Quintiles Transnational Holdings Inc was founded in February 1982. The Company completed its initial public offering on May 9, 2013. The Company is engaged in providing biopharmaceutical development services and commercial outsourcin...g services. The Company’s services offerings, helps biopharmaceutical customers, as well as customers in the healthcare industry, to make decisions regarding drug development, commercialization and drug therapy choices. The Company offers services through two segments Product Development; and Integrated Healthcare Services. The Product Development segment provides services and expertise that allow biopharmaceutical companies to outsource the clinical development process from first-in-man trials to post-launch monitoring. Its service offering provides the support and func...tional expertise necessary at each stage of development, as well as the systems and analytical capabilities to help customers improve product development efficiency and effectiveness. It is comprised of clinical solutions and services and consulting. Clinical solutions and services provide services to develop biopharmaceutical products including project management and clinical monitoring functions for conducting multi-site trials; clinical trial support services that improve clinical trial decision-making, such as global laboratories, data management, bio-statistical, safety and pharmacovigilance, early clinical development trials and strategic planning and design services. Consulting provides strategy and management consulting services based on life science expertise and advanced analytics, as well as regulatory and compliance consulting services. The Integrated Healthcare Services segment provides the healthcare industry with both geographic presence and commercial capabilities. Its customized commercialization services are designed to accelerate the commercial success of biopharmaceutical and other health-related products. It provides services including commercial services, such as providing contract pharmaceutical sales forces in geographic markets, as well as a growing number of healthcare business services for the broader healthcare sector. Its service offerings include commercial services and other healthcare services. The Company faces competition from traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Its competitors include; Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research, PRA International, United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan. In the United States, pharmaceutical, biological and medical device products are subject to extensive regulation by the FDA. Its integrated healthcare services are subject to numerous federal and state laws pertaining to promotional activities involving pharmaceutical products and medical devices, such as the FDA’s regulations against “off-label promotion,” which require sales representatives to restrict promotion of the approved product they are detailing to the approved labeling for the product, and the Prescription Drug Marketing Act which imposes licensing, personnel record keeping, packaging, labeling, product handling and facility storage and security requirements.